Topotecan versus paclitaxel in second-line therapy: a lost opportunity for quality-of-life evaluation?
Apolone
G
G
Buda
A
A
D000970:Antineoplastic Agents / Q000627:therapeutic use*; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D009375:Neoplasms, Glandular and Epithelial / Q000188:drug therapy; D010051:Ovarian Neoplasms / Q000188:drug therapy; D017239:Paclitaxel / Q000627:therapeutic use*; D011788:Quality of Life; D013997:Time Factors; D019772:Topotecan / Q000627:therapeutic use*; D016896:Treatment Outcome
D000970:Antineoplastic Agents; D019772:Topotecan; D017239:Paclitaxel